Rafat Abonour, MD
Hematology · Indianapolis, INNPI 1750346755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $434,977 of the $712,003 with a category attached, or 61.1%. 17 manufacturers reported payments, led by Johnson & Johnson at 53.0% of the total.
Across 483 payments — averaging $1474.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$377K
- Takeda Pharmaceuticals U.S.A., Inc.$85K
- GSK$76K
- Pfizer$60K
- E.r. Squibb & Sons, L.L.C.$37K
- Bristol Myers Squibb$35K
- plus $42K from 11 others
Across 234 payments — averaging $17,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.5M
- Janssen Research & Development, LLC$721K
- Bristol Myers Squibb$644K
- AstraZeneca$372K
- GSK$307K
- Genentech, Inc.$295K
- plus $335K from 2 others
What the payments were for
- Consulting fees$177,74825%
- Speaking & faculty fees$434,97761%
- Grants$1,0700%
- Travel & lodging$87,17812%
- Food & beverage$10,9222%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 284 | $377,075 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $85,473 |
| GSK | 36 | $75,510 |
| Pfizer | 35 | $59,957 |
| E.r. Squibb & Sons, L.L.C. | 26 | $37,227 |
| Bristol Myers Squibb | 40 | $34,502 |
| Amgen | 11 | $19,939 |
| Regeneron Healthcare Solutions, Inc. | 5 | $7,622 |
| AbbVie | 4 | $5,470 |
| Adaptive Biotechnologies Corporation | 7 | $3,006 |
| Genentech, Inc. | 3 | $2,840 |
| Sanofi | 3 | $1,854 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Genmab U.S., Inc. | 1 | $124 |
| Gilead | 1 | $122 |
| Karyopharm Therapeutics Inc. | 2 | $114 |
| Legend Biotech USA Inc. | 2 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 128 | $1,801,659 |
| RevlimidLenalidomide | 40 | $734,701 |
| PomalystPomalidomide | 35 | $583,428 |
| NinlaroIxazomib Citrate | 29 | $372,702 |
| BrukinsaZanubrutinib | 24 | $149,568 |
| EliquisApixaban | 58 | $45,940 |
| Acyclovir | 447 | $8,532 |
| Fentanyl | 19 | $4,488 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $1,744 |
| ValacyclovirValacyclovir Hcl | 16 | $1,600 |
| Oxycodone Hcl | 58 | $1,432 |
| CholestyramineCholestyramine (With Sugar) | 21 | $1,057 |
| Potassium Chloride | 34 | $850 |
| Gabapentin | 44 | $782 |
| Cholestyramine LightCholestyramine | 11 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $34,502 | $734,70140 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $37,227 | $583,42835 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $85,473 | $372,70229 claims |
| PfizerEliquis | $59,957 | $45,94058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other hematology in Indianapolis
- Luke AkardIndianapolis$358K
- Felix MensahIndianapolis$152K
- Brandon HardestyIndianapolis$72K
- Lalitha NayakIndianapolis$11K
- Fatemeh Ardeshir LarijaniIndianapolis$3K
- Varun MittalIndianapolis$363
- Jennifer SchwartzIndianapolis$108
- Kenneth OforiIndianapolis$51
- Rakesh MehtaIndianapolis$13
- Sherif FaragKokomo$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.